Which organisations are collaborating on the development of this new Ebola vaccine?

Question

Accepted Answer

Organisations Collaborating on New Ebola Vaccine Development

Hilleman Laboratories, a joint venture between MSD and the Wellcome Trust, is leading the development of a new Ebola vaccine. MSD, also known as Merck in North America, will provide technical expertise on the rVSV platform. The Coalition for Epidemic Preparedness Innovations (CEPI) is contributing funds to support the rVSV shot and other Ebola vaccine initiatives.
Hilleman Laboratories' Role in Vaccine Development

Hilleman Laboratories, based in Singapore, has announced its commitment to advancing a Bundibugyo strain Ebola vaccine candidate. This organisation is a collaborative effort between the US pharmaceutical giant MSD and the British charity Wellcome Trust. Hilleman Laboratories aims to prepare doses for human clinical trials of the rVSV Bundibugyo jab.
MSD's Technical Contribution

MSD, a key partner in Hilleman Laboratories, will act as a technical adviser for the vaccine development. The company brings its extensive experience with the rVSV platform, which it previously used to develop and manufacture the Ervebo Ebola vaccine. This expertise is crucial for advancing the new vaccine candidate.
CEPI's Financial Support

The Coalition for Epidemic Preparedness Innovations (CEPI) has pledged financial support for the rVSV Ebola vaccine. This funding is designated for the rVSV shot and other related Ebola vaccine research and development efforts. CEPI's involvement aims to ensure that if the vaccine proves successful, there can be rapid and affordable access to doses in affected countries and low- and middle-income settings.

Reading history

Hide →

This history is cleared when the page is closed.

Which organisations are collaborating on the development of this new Ebola vaccine?

Loading

Was this article helpful?

Helpful

Not helpful

Report an issue

1

0

0

Share with friends